RXRX

In the past six months, RXRX's share price declined 13.56% from $5.53 to $4.78, though it recently bounced approximately 40% from $3.20 to the mid-$4s. The stock has traded between a 52-week low of $2.77 and a 52-week high of $7.18. A significant trading volume spike in October 2025 was linked to ATM share issuance and scientific milestones. In Q3 2026, Recursion reported revenues of $5.18 million, an 80.2% year-over-year decline, missing Wall Street expectations and raising concerns, despite a $30 million milestone from Roche/Genentech. In July 2023, Nvidia announced a $50 million strategic partnership with Recursion. More recently, in October 2026, the stock saw heavy call option buying, but also experienced volatility due to traders cashing out after a rally from an extended data license deal with Tempus AI, and a director's plan to sell shares. Recursion reported Q1 financial results and a business update on May 6, 2026, and its stock has historically declined an average of 1.6% on the first day after earnings reports.